HomeCompareSLRN vs HDV

SLRN vs HDV: Dividend Comparison 2026

SLRN yields 88.11% · HDV yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRN wins by $2.34M in total portfolio value
10 years
SLRN
SLRN
● Live price
88.11%
Share price
$2.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.37M
Annual income
$731,873.50
Full SLRN calculator →
HDV
iShares Core High Dividend ETF
● Live price
2.92%
Share price
$135.39
Annual div
$3.96
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$352.73
Full HDV calculator →

Portfolio growth — SLRN vs HDV

📍 SLRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRNHDV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRN + HDV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRN pays
HDV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRN
Annual income on $10K today (after 15% tax)
$7,488.99/yr
After 10yr DRIP, annual income (after tax)
$622,092.48/yr
HDV
Annual income on $10K today (after 15% tax)
$248.52/yr
After 10yr DRIP, annual income (after tax)
$299.82/yr
At 15% tax rate, SLRN beats the other by $621,792.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRN + HDV for your $10,000?

SLRN: 50%HDV: 50%
100% HDV50/50100% SLRN
Portfolio after 10yr
$1.20M
Annual income
$366,113.11/yr
Blended yield
30.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SLRN right now

SLRN
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Price Target
$10.50
+362.6% upside vs current
Range: $6.00 — $15.00
Altman Z
1.6
Piotroski
2/9
HDV
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRN buys
0
HDV buys
0
No recent congressional trades found for SLRN or HDV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRNHDV
Forward yield88.11%2.92%
Annual dividend / share$2.00$3.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$2.37M$24.3K
Annual income after 10y$731,873.50$352.73
Total dividends collected$2.08M$3.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SLRN vs HDV ($10,000, DRIP)

YearSLRN PortfolioSLRN Income/yrHDV PortfolioHDV Income/yrGap
1← crossover$19,511$8,810.57$11,002$292.38+$8.5KSLRN
2$36,942$16,065.36$12,084$300.36+$24.9KSLRN
3$67,956$28,428.44$13,250$308.02+$54.7KSLRN
4$121,587$48,874.33$14,506$315.35+$107.1KSLRN
5$211,824$81,725.42$15,858$322.35+$196.0KSLRN
6$359,715$133,063.84$17,313$329.04+$342.4KSLRN
7$596,079$211,183.71$18,878$335.42+$577.2KSLRN
8$964,860$327,055.60$20,560$341.49+$944.3KSLRN
9$1,527,165$494,764.27$22,367$347.25+$1.50MSLRN
10$2,365,940$731,873.50$24,307$352.73+$2.34MSLRN

SLRN vs HDV: Complete Analysis 2026

SLRNStock

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Full SLRN Calculator →

HDVETF

The iShares Core High Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full HDV Calculator →
📬

Get this SLRN vs HDV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRN vs SCHDSLRN vs JEPISLRN vs OSLRN vs KOSLRN vs MAINSLRN vs VYMSLRN vs DVYSLRN vs SPHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.